MRK · 10-Q · 2026Q2 · Full report

Animal Health Demand

Merck & Co., Inc. · 2026-08-07 · Importance 36 · Surprise 40

Livestock product sales grew 8% in the second quarter and 12% in the first six months of 2026, primarily from higher ruminant and poultry demand. Companion animal sales increased 7% and 8%, respectively, supported by new product launches despite lower demand for other portfolio products. Bravecto sales reached $359 million in the second quarter and $738 million in the first six months, with reported growth of 7% and 11%, respectively.

Key facts

• Bravecto line sales were $359 million in Q2 2026 (growth of 7%, or 4% excluding FX) and $738 million in the first six months of 2026 (growth of 11%, or 7% excluding FX). source
• Animal health livestock sales grew 8% and 12% in the second quarter and first six months of 2026, respectively, primarily due to higher demand for ruminant and poultry products. source
• Animal health companion animal sales grew 7% and 8% in the second quarter and first six months of 2026, respectively, primarily due to new product launches. source